These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 9892155

  • 1. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
    Brown L, Duce B, Miric G, Sernia C.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
    [Abstract] [Full Text] [Related]

  • 2. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
    Brilla CG, Scheer C, Rupp H.
    J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
    [Abstract] [Full Text] [Related]

  • 3. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M.
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [Abstract] [Full Text] [Related]

  • 4. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
    Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K.
    J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
    [Abstract] [Full Text] [Related]

  • 5. Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
    Fujita H, Takeda K, Miki S, Morimoto S, Kawa T, Uchida A, Itoh H, Nakata T, Sasaki S, Nakagawa M.
    Hypertens Res; 1997 Dec; 20(4):263-7. PubMed ID: 9453261
    [Abstract] [Full Text] [Related]

  • 6. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T.
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [Abstract] [Full Text] [Related]

  • 7. Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
    Hara K, Kobayashi N, Watanabe S, Tsubokou Y, Matsuoka H.
    Am J Hypertens; 2001 Apr; 14(4 Pt 1):321-30. PubMed ID: 11336177
    [Abstract] [Full Text] [Related]

  • 8. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
    Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb NE.
    Hypertension; 2001 Mar; 37(3):974-80. PubMed ID: 11244026
    [Abstract] [Full Text] [Related]

  • 9. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
    Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S.
    Hypertension; 2003 Mar; 41(3):493-8. PubMed ID: 12623949
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
    Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L.
    J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
    [Abstract] [Full Text] [Related]

  • 11. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
    Pollock DM, Derebail VK, Yamamoto T, Pollock JS.
    Gen Pharmacol; 2000 May; 34(5):337-42. PubMed ID: 11368889
    [Abstract] [Full Text] [Related]

  • 12. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 13. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
    O'Brien D, Chunduri P, Iyer A, Brown L.
    Basic Clin Pharmacol Toxicol; 2010 Apr 02; 106(4):296-301. PubMed ID: 20041879
    [Abstract] [Full Text] [Related]

  • 14. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
    Kim S, Iwao H.
    J Hypertens Suppl; 1997 Dec 02; 15(6):S3-7. PubMed ID: 9493120
    [Abstract] [Full Text] [Related]

  • 15. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
    Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M.
    J Hypertens; 1998 Aug 02; 16(8):1175-85. PubMed ID: 9794722
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
    Nishikawa K.
    J Hum Hypertens; 1998 May 02; 12(5):301-9. PubMed ID: 9655651
    [Abstract] [Full Text] [Related]

  • 17. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
    Pollock DM, Morsing P.
    J Am Soc Nephrol; 1999 Jan 02; 10 Suppl 11():S116-9. PubMed ID: 9892151
    [Abstract] [Full Text] [Related]

  • 18. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
    Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T.
    Kidney Int Suppl; 1997 Dec 02; 63():S229-31. PubMed ID: 9407467
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
    Watanabe K, Juan W, Narasimman G, Ma M, Inoue M, Saito Y, Wahed MI, Nakazawa M, Hasegawa G, Naito M, Tachikawa H, Tanabe N, Kodama M, Aizawa Y, Yamamoto T, Yamaguchi K, Takahashi T.
    J Cardiovasc Pharmacol; 2003 Jan 02; 41 Suppl 1():S93-7. PubMed ID: 12693379
    [Abstract] [Full Text] [Related]

  • 20. Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension.
    Zeng ZH, Luo BH, Gao YJ, Su CJ, He CC, Yi JJ, Li N, Lee RM.
    Eur J Pharmacol; 2004 Oct 25; 503(1-3):129-33. PubMed ID: 15496307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.